Umeå University's logo

umu.sePublikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Serological evidence of substantial respiratory syncytial virus infection burden among older adults residing in Swedish long-term care facilities
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.ORCID-id: 0000-0002-7773-3240
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi.ORCID-id: 0009-0001-5257-8109
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk mikrobiologi. Public Health Agency of Sweden, Solna, Sweden.
Division of Immunology and Respiratory Medicine, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.
Vise andre og tillknytning
2026 (engelsk)Inngår i: BMC Medicine, E-ISSN 1741-7015, Vol. 24, nr 1, artikkel-id 134Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background: Older adults (> 65 years) residing in long-term care facilities (LTCFs) are at elevated risk of severe outcomes from respiratory infections. Infections often remain undetected or present atypically in this population, leading to underdiagnosis. Our study aimed to estimate the respiratory virus infection burden, independent of symptom presentation, among older adults in Swedish LTCFs in the post-pandemic period (2021–2024).

Methods: We leveraged capillary blood samples and coupled national registry data from 1622 LTCF residents (median age = 87). A multiplex platform was used to quantify antigen-specific IgG and IgM responses to RSV (pre-/post-F, strain A-specific G-protein), influenza-A (H1N1 and H3N2 HA), influenza-B (HA) and SARS-CoV-2 (spike). Linear mixed-effects models were used to demonstrate the dynamics of antibody levels over time, adjusted for age, sex and comorbidities.

Results: RSV-specific antibody responses peaked in spring 2022 (p < 0.001), suggesting an impact of relaxed COVID-19-related restrictions on RSV exposure at LTCFs. RSV-specific antibodies subsequently declined over time until an increase during autumn 2023 (p < 0.001). Geographic variation in pre-F antibody levels suggested localised RSV outbreaks. The total estimated RSV burden at LTCFs was markedly higher than official reports of the Swedish Public Health Agency. Influenza antibody dynamics reflected seasonal trends and were strongly influenced by annual vaccination. A random forest classifier incorporating serological profiles with demographics, location and comorbidities significantly outperformed a model without serological data (AUC-ROC = 0.67 vs. 0.58), although discriminatory performance remained modest. Higher levels of RSV pre-F antibodies in autumn 2021 were associated with increased one-year mortality in logistic regression (OR = 1.43, p = 0.024). Exploratory survival analysis indicated a trend that elevated levels of RSV pre-F antibodies during low population immunity may confer a transiently elevated early hazard of death, although this did not reach statistical significance (HR = 4.50, p = 0.087).

Conclusions: We observed substantial respiratory virus circulation among older adults in Swedish LTCFs and show that RSV burden is under-reported. The results highlight a need for further research into the role of RSV pre-F antibody levels in preventing severe outcomes, potentially via vaccination of LTCF residents. Our scalable serological surveillance system is a valuable approach to detect respiratory infections in LTCFs, independent of symptom presentation or healthcare-seeking behaviour.

sted, utgiver, år, opplag, sider
BioMed Central (BMC), 2026. Vol. 24, nr 1, artikkel-id 134
Emneord [en]
Immune monitoring, Influenza, Longitudinal sampling, Mortality, Population immunity, Risk factors, RSV, SARS-CoV-2, Vaccination, Vulnerable/ high risk population
HSV kategori
Identifikatorer
URN: urn:nbn:se:umu:diva-250938DOI: 10.1186/s12916-026-04700-7ISI: 001705105500001PubMedID: 41731510Scopus ID: 2-s2.0-105031601965OAI: oai:DiVA.org:umu-250938DiVA, id: diva2:2046534
Forskningsfinansiär
Swedish Research Council, 2020–06235Swedish Research Council, 2024–03244Region Västerbotten, RV-993597Tilgjengelig fra: 2026-03-17 Laget: 2026-03-17 Sist oppdatert: 2026-03-17bibliografisk kontrollert

Open Access i DiVA

fulltext(1688 kB)60 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1688 kBChecksum SHA-512
c2a46d33be7e16a7f356a5afe0c86dab04462def3af96738b6389dd7cb5bea4ee7b60b38cebdd38e7ef03a14d10c872bd155b48df0842586cb5a4f91424d88ea
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMedScopus

Person

Moar, PreetiGranvik, ChristofferBlom, KimWigren Byström, JuliaFjällström, PeterNormark, JohanJohansson, AndersForsell, Mattias N. E.

Søk i DiVA

Av forfatter/redaktør
Moar, PreetiGranvik, ChristofferBlom, KimWigren Byström, JuliaFjällström, PeterNormark, JohanJohansson, AndersForsell, Mattias N. E.
Av organisasjonen
I samme tidsskrift
BMC Medicine

Søk utenfor DiVA

GoogleGoogle Scholar
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 1670 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf